PT  - JOURNAL ARTICLE
AU  - Buckley, Rita
ED  - Kastrati, Adnan
TI  - ISAR-REACT 4 – Bivalirudin Similar to Abciximab/Heparin in Reducing Ischemic Outcomes in NSTEMI and Has Significantly Less Bleeding
DP  - 2011  01
TA  - MD Conference Express
PG  - 14--15
VI  - 11
IP  - 15
4099  - http://mdc.sagepub.com/content/11/15/14.short
4100  - http://mdc.sagepub.com/content/11/15/14.full
AB  - A strategy of intravenous abciximab (a glycoprotein [GP] IIb/IIIa inhibitor) plus unfractionated heparin, compared with bivalirudin, an IV direct thrombin inhibitor, failed to improve clinical outcomes and increased the risk of bleeding in patients with acute non-ST-segment elevation myocardial infarction (NSTEMI) who were undergoing percutaneous coronary intervention, according to results of the ISAR-REACT 4 trial [NCT00373451].